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Lung neoplasm, in place of gastric cancer, is the major cause of
cancer mortality in Japan as well as in the USA (Travis et al,
1995). Despite the advances in diagnostic techniques for the early
detection of lung cancer and the significant improvement in
surgical procedures, the survival rate of lung cancer patients is
poor even in the early stages of cancer as compared to the other
malignant neoplasms. From a clinical point of view, one of the
most troublesome impediments for treatment of lung cancer is the
metastasis to mediastinal lymph nodes (n = 2 and n = 3 lung
cancer) from the primary lesion (Jefferson et al, 1996). If metas-
tases were inhibited by the present and/or new therapies, the prog-
nosis of patients with lung cancer would improve. According
to new TNM revisions (Mountain, 1997), it is difficult to say if the
5-year survival rate of n ‡ 2 in lung cancer patients is an improve-
ment, although a standard operative technique has been estab-
lished to resect mediastinal lymph nodes (Vansteenkiste et al,
1997), except for aortic lymph node metastasis (Nakanishi et al,
1997). Therefore, biological approaches and studies, such as
interference with lymph node metastasis or management of down-
staging to the patients with lymph node metastasis, combined with
surgery are required for lung cancer therapy. To do this, suitable
animal models that conform to the clinical features are also neces-
sary to search for novel therapies of lung cancer and to evaluate
the efficacy of new drugs. However, there are few models for the
formation of a solitary pulmonary nodule by orthotopic implan-
tation of lung cancer cells and subsequent lymph node metastasis.
In the present study, we attempted to establish a simple model
for a solitary lung tumour and its lymph node metastasis by intra-




Specific pathogen-free female C57BL/6 mice at 6 weeks old, were
purchased from Japan SLC, Inc, Hamamatsu, Japan. They were
maintained in the Laboratory for Animal Experiments, Research
Institute for Wakan-Yaku Toyama Medical and Pharmaceutical
University, under laminar air-flow conditions. All animals had free
access to standard laboratory mouse food and water ad libitum.
Housing was temperature controlled with a 12-h light and dark
cycle. This study was conducted in accordance with the standards
established by the Guidelines for the Care and Use of Laboratory
Animals of Toyama Medical and Pharmaceutical University.
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Summary This study is designed to establish a pulmonary tumour model to investigate the biology and therapy of lung cancer in mice.
Current methods for forming a solitary intrapulmonary nodule and subsequent metastasis to mediastinal lymph nodes are not well defined.
Lewis lung carcinoma (LLC) cell suspensions were orthotopically introduced into the lung parenchyma of C57/BL6 mice via a limited skin
incision without thoracotomy followed by direct puncture through the intercostal space. The implantation process was performed within
approximately 50 s per mouse, and the operative mortality was less than 5%. Single pulmonary nodules developed at the implanted site in
93% of animals and subsequent mediastinal lymph node metastasis was observed in all mice that formed a lung nodule after intrapulmonary
implantation. The size of tumour nodule and the weight of mediastinal lymph node increased in a time-dependent manner. The mean survival
time of mice implanted successfully with LLC cells was 21 ± 2 days (range 19–24 days). Histopathological analysis revealed that no
metastatic tumour was detectable in the mediastinal lymph nodes on day 11, but metastatic foci at mediastinal lymph nodes were clearly
observed on days 17 and 21 after implantation. Other metastases in distant organs or lymph nodes were not observed at 21 days after the
implantation. Comparative studies with intrapleural and intravenous injections of LLC cells suggest that the mediastinal lymph node
metastasis by intrapulmonary impantation is due to the release of tumour cells from the primary nodule, and not due to extrapulmonary
leakage of cells. An intravenous administration of cis-diamine dichrolo platinum on day 1 after tumour implantation tended to suppress the
primary tumour nodule and significantly inhibited lymph node metastasis. Thus, a solitary pulmonary tumour nodule model with lymph node
metastasis approximates clinical lung cancer and may provide a useful basis for lung cancer research.
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LLC cells, originated spontaneously from mouse lung, were kindly
provided by Dr K Takeda, Tohoku University, Tohoku, Japan. They
were maintained as monolayer cultures in Eagle￿s minimal essen-
tial medium (EMEM) supplemented with 7.5% fetal bovine serum
(FBS), vitamine solution, sodium pyruvate, non-essential amino
acid, and L-glutamine (MA Bioproducts, Walkersville, MD, USA).
Chemicals
CDDP (cis-diamine dichrolo platinum; randa¤, 0.5 mg/ml)
was purchased from Nippon Kayaku Co., Ltd, Tokyo, Japan.
Matrigel¤ basement membrane matrix, possessing the ability to
gel rapidly at 22—35°C, was purchased from Collaborative
Biomedical Products, Bedford, MA, USA.
Intrapulmonary implantation procedure
Log-phase cell cultures of LLC cells were harvested with 1 mM
EDTA in phosphate buffered saline (PBS), washed three times
with serum-free EMEM, and resuspended at a cell density of
5 ´ 104/ml in PBS containing 500 mg/ml of Matrigel¤. Animals
were anaesthetized with ether. The left chest was swabbed with
70% alcohol and a small skin incision to the left chest wall
(approximately 5 mm in length) was made at about 5 mm tail side
from the scapula. Subskin fat and muscles were separated from
costal bones. On observing the left lung motion through the pleura,
a 29 gauge needle attached to a 0.5 ml insulin syringe was directly
inserted through the intercostal space into the lung to a depth of
3 mm. Tumour cells (1 ´ 103) were suspended in 20 ml of PBS
containing 10 mg of Matrigel¤ to prevent the suspension from
leaking out of the lung, and were then injected into the lung
parenchyma. A cotton-tipped applicator was pressed on the site of
puncture as the needle was withdrawn to stop any bleeding. The
skin incision was closed with a surgical skin clip. After confirming
that the animals had recovered from bradycardia and possessed
stable spontaneous respiration, they were returned to their cages.
Macroscopic findings and histological study
Mice were sacrificed at various time periods (on days 11, 17 and
21) after tumour implantation, and the long and short diameters of
the primary tumour mass and the weight of mediastinal lymph
nodes for evaluating metastasis were measured manually. The
tumour volume was calculated by the following formula: tumour
volume (mm3) = 1/2 ´ (long diameter) ´ (short diameter)2. The
lungs with a primary tumour nodule and mediastinal lymph nodes
were excised for histological examination. In another experiment
to evaluate the inhibitory effect of CDDP, mice were injected
intravenously (i.v.) with CDDP at the clinical equivalent dose of
7 mg/kg (Nomura et al, 1996) after intrapulmonary implantation
of LLC cells. T/C(%) of tumour growth was determined according
to the formula: T/C(%) of tumour growth = (mean tumour growth
of treated groups)/(mean tumour growth of untreated control
groups)  ´ 100.
Statistical analysis
The statistical significance of differences between the groups was
determined by applying the Student￿s two-tailed t-test or the
Mann—Whitney  U-test.
RESULTS
Mediastinal lymph node metastasis by orthotopic
implantation of LLC cells
LLC cells (1 ´ 103) were orthotopically injected through the inter-
costal space into the lung immediately after a small skin incision.
The skin incision followed by intrapulmonary implantation of
LLC cells was performed within approximately 50 s per mouse,
and the operative mortality was less than 5%. Mean survival time
of mice implanted successfully with LLC cells was 21 ± 2 days
(range 19—24 days). In several experiments, tumours developed at
the site of direct implantation in 93% (74/80) of animals, and all
cases that formed a nodule in the lung had subsequent mediastinal
lymph node metastasis. As shown in Figure 1, the implanted
LLC cells developed a primary nodule in the lung which grew
large as a function of time. The tumour volumes increased in
a time-dependent manner, and were 0.75 ± 0.3, 34.7 ± 20 and
143 ± 134 mm3 on days 11, 17 and 21 after the implantation,
respectively (Figure 2). Tumours were visible to the naked eye in
approximately 7 days. In addition, metastases to mediastinal
lymph nodes were observed on days 17 and 21 after the implanta-
tion (Figure 1). A marked increase in the weight of the lymph
nodes with a cobble stone-like appearance was macroscopically
seen on day 21 (Figures 1 and 2). Similar to the tumour volume,
the weight of resected mediastinal lymph nodes increased in a
time-dependent manner (506 ± 213 and 1529 ± 759 mg on days 17
and 21, respectively). In these experiments, no unexpected tumour
growth into the chest wall or pleural disseminations were seen.
Histopathological observation
We next investigated the histopathological determination of the
resected primary tumour and mediastinal lymph nodes on days 11,
17 and 21 after the implantation. Figure 3 shows that tumor cells
proliferated uniformly and intimately all over the specimen on
days 11 and 17, and central necrosis with bleeding in the nodule
was observed on day 21. In addition, no metastatic tumour was
seen in the mediastinal lymph nodes on days 11, but metastatic
foci were clearly observed on days 17 and 21 after implantation
(Figure 4). No metastatic nodule was macroscopically observed in
distant organs and lymph nodes such as liver, spleen and cervical
and supra/sub clavian lymph nodes, even on day 21 (moribund
state) after implantation.
Effect of CDDP on tumour growth and lymph node
metastasis produced by intrapulmonary implantation of
LLC cells
To evaluate the efficacy of anti-cancer drugs in this model, mice
were injected i.v. with CDDP at the clinical equivalent dose of
7 mg/kg (Nomura et al, 1996) on day 1 or 10 after intrapulmonary
implantation of LLC cells. The primary tumour volumes and the
weight of mediastinal lymph nodes were measured on day 18 after
implantation. Administration of CDDP on day 1 tended to suppress
the primary tumour volumes as compared with the untreated
control, whereas the weight of mediastinal lymph nodes was signif-
icantly inhibited by treatment with CDDP (P < 0.01) (Experiment
1, Figure 5). The tumour volumes and weight of lymph nodes
in control and CDDP-treated groups were 128.7 ± 95.6 and
65.5  ± 82.3 mm3, and 316 ± 226 and 97 ± 135 mg, respectively
(Experiment 1, Figure 5). When CDDP was administered i.v. on
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tumour volumes, but tended to inhibit the weight of lymph nodes
although the effect was not significant (Experiment 2, Figure 5).
DISCUSSION
In the present study, we have established a useful model for a soli-
tary pulmonary tumor and subsequent metastasis to mediastinal
lymph nodes by intrapulmonary implantation of LLC cells in
syngeneic immunocompetent mice. An advantage of this model
includes the simple and easy implantation procedure with a small
skin incision at a predetermined site followed by direct puncturing
through the intercostal space to lung parenchyma, without thoraco-
tomy or intubation. The whole implantation process was
performed within approximately 50 s per mouse, and the operative
mortality was less than 5%. Tumours developed at the site of direct
implantation in 93% of animals.
Several studies have shown that the biological behaviour of
human tumour cells is influenced by the implantation site (Fidler,
1986), and that the orthotopic implantation of human tumour cells
into relevant organs of nude mice can provide an in vivo model
to study the biology and therapy of these cells (Fidler, 1986;
McLemore et al, 1988). Orthotopic nude mouse or nude rat
models have been developed for a number of human cancers
including those of lung, colon, kidney and pancreas (Tan and Chu,
1985; Naito et al, 1986; McLemore et al, 1987; Morikawa et al,
1988). In particular, orthotopic models for human lung cancer have
been reported by several investigators (McLemore et al, 1988,
1997; Wang and Hoffman, 1992); however, they have some prob-
lems such as the complicated procedures including thoracotomy
(Wang and Hoffman, 1992) or intubation, long observation times
and the necessity of immunosuppression by some agents (Yano et
al, 1996) or irradiation (Howard et al, 1991) to increase the take-
rate of tumours. Previous studies have shown that ectopic implan-
tations such as i.v., subcutaneous (s.c.) or intrafootpad injections
of lung cancer cells achieved the formation of secondary tumours
in lung (Talmadge and Fidler, 1982; Brodt, 1986), although their
use as a lung cancer model may not reflect the clinical course of
primary lung cancer. Recently, Wang et al (1997) have shown a
simple model in which chemically-induced sarcoma cells were
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Day11 Day17 Day21
Figure 1 Macroscopic findings of resected lung and mediastinum on various days after intrapulmonary implantation of LLC cells. The implanted tumour cells
formed a pulmonary nodule in the lung and the tumour sizes increased with time. The metastases to mediastinal lymph nodes were visible on days 17 and 21
after implantation (®)
Day 11 Day 17 Day 21directly implanted to the lung of thoracotomized Fisher-344 rat,
but this is not an orthotopic implantation model.
Matrigel¤ has been used as a standard procedure for efficient
formation of tumours, especially high take-rate by s.c. implantation
of human tumours in athymic mice (Friedman et al, 1990, 1991).
As shown in Figures 1 and 2, orthotopic implantation of LLC cells
suspended in PBS containing Matrigel¤ resulted efficiently in the
formation of a solitary tumour nodule, and the tumour volume
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Figure 2 Changes in tumour volumes and weights of mediastinal lymph nodes on various days after intrapulmonary implantation of LLC cells. Five mice per
group were orthotopically inoculated with LLC cells (1 ´ 103) and at various days later, the tumour sizes and weight of mediastinal lymph nodes were measured.




Figure 3 Pathological findings of the pulmonary tumour nodule on various days after intrapulmonary implantation of LLC cells. Central necrosis was
extensively observed in comparison with the proliferative growth in peripheral area of the nodule on day 21. (A) ´ 50, (B) ´ 250
Day 11 Day 17 Day 21increase was time-dependent. Similarly, the increase in the weight
of mediastinal lymph nodes was observed in a time-dependent
manner. In our preliminary studies, intrapulmonary implantation of
cell suspension containing dye as an indicator without Matrigel¤
caused rapid dispersion and extrapulmonary leakage of the
dye within approximately 20 s after the injection, while the
implantation of cell suspension with Matrigel¤ (500 mg/ml), which
has the ability to gel rapidly at 22—35°C, showed clear localization
of the dye at the injection site of lung. In addition, intrapulmonary
or intrapleural injections of LLC cells without Matrigel¤ showed
no formation of the solitary nodule on day 17, while pleural dissem-
ination was observed (data not shown). Intravenous injection of
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Figure 4 Pathological findings of the mediastinal lymph nodes on various days after intrapulmonary implantation of LLC cells. No metastatic lesion was seen
on day 11, whereas certain metastases were observed on days 17 and 21, central necrosis of tumour was also seen on day 21. (A) ´ 50, (B) ´ 250
Figure 5 Effect of CDDP on the growth of the orthotopically implanted tumour and metastasis to mediastinal lymph nodes. Seven or four C57BL/6 mice per
group (Experiments 1 or 2) were injected with LLC cells (1 ´ 103) suspended in PBS containing 10 mg Matrigel® into the left lung. CDDP (7 mg/kg) was given i.v.
on day 1 (Experiment 1) or 10 (Experiment 2) after tumour implantation. Mice were sacrificed on day 18, and then primary tumour size and the weight of
mediastinal lymph nodes were measured. **P < 0.01 by Student’s two-tailed t-test
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Day 11 Day 17 Day 21tumour cells also caused the formation of multiple metastatic
colonies in lung. On the other hand, metastases to mediastinal
lymph nodes were observed by any injection route of the tumour
cells. These results indicate that the suspending of tumour cells
in Matrigel¤ resulted in the efficient formation of a solitary
pulmonary nodule by implantation, and prevented the tumour cell
suspension from leaking out of the lung, which would consequently
lead to extrapulmonary tumour growth. Since pleural dissemination
was not observed after intrapulmonary implantation of tumour cells
with Matrigel¤, which is different from the case of intrapleural
injection, the metastasis to mediastinal lymph nodes would be due
to the release of tumour cells from the primary nodule, and not due
to extrapulmonary leakage of tumour cells.
Matrigel¤ has been shown to influence the behaviour and
aggressiveness of tumours, such as promotion of tumorigenicity
and invasiveness, drug resistance and induction of vascularization
(Friedman et al, 1990, 1991; Yamamura et al, 1993; Bonfil et al,
1994; Ito et al, 1996). Mice bearing primary nodules in lungs
showed 100% incidence of mediastinal lymph node metastasis.
Thus, the co-injection with Matrigel¤ may lead to the enhance-
ment of lymph node metastasis as well as the formation of primary
tumour through the above mentioned properties of Matrigel¤.
To investigate the usefulness of this model for evaluating anti-
cancer drugs, we also examined the effect of CDDP as a major
drug used for clinical chemotherapy on primary tumour growth
and lymph node metastasis in our intrapulmonary implantation
model (Figure 5). A single administration of the clinical equiva-
lent dose of CDDP (Nomura et al, 1996) on day 1 after intrapul-
monary implantation of LLC cells tended to suppress primary
tumour growth and significantly inhibited metastasis to medi-
astinal lymph nodes. CDDP administration on day 10 did not
affect primary tumour growth, but tended to inhibit lymph node
metastasis. This indicates that the inhibition of mediastinal lymph
node metastasis by CDDP may be due to the growth inhibition of
both primary tumour and metastatic tumour in lymph nodes.
However, further study will be needed to determine the timing of
the administration and schedules for evaluating the exact efficacy.
Our model using murine lung carcinoma cells in syngeneic
immunocompetent mice may also be useful for evaluating the
efficacy of some biological response modifiers which possess the
immunomodulating properties.
Thus, our solitary pulmonary tumour nodule model with lymph
node metastasis approximates clinical lung cancer. This procedure
is simple and reproducible with a low implantation mortality and a
high rate of solitary nodule development, because it involves only
a small skin incision followed by direct puncturing through the
intercostal space to the lung parenchyma, without thoracotomy or
intubation. Therefore, this model may provide a useful basis for
lung cancer research.
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